Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 3
2015 4
2016 7
2017 1
2018 3
2019 4
2020 4
2021 1
2022 1
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Gisslinger H, et al. Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31. Lancet Haematol. 2020. PMID: 32014125 Clinical Trial.
Curcumin: New Insights into an Ancient Ingredient against Cancer.
Willenbacher E, Khan SZ, Mujica SCA, Trapani D, Hussain S, Wolf D, Willenbacher W, Spizzo G, Seeber A. Willenbacher E, et al. Int J Mol Sci. 2019 Apr 12;20(8):1808. doi: 10.3390/ijms20081808. Int J Mol Sci. 2019. PMID: 31013694 Free PMC article. Review.
Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing.
Rensing-Ehl A, Lorenz MR, Führer M, Willenbacher W, Willenbacher E, Sopper S, Abinun M, Maccari ME, König C, Haegele P, Fuchs S, Castro C, Kury P, Pelle O, Klemann C, Heeg M, Thalhammer J, Wegehaupt O, Fischer M, Goldacker S, Schulte B, Biskup S, Chatelain P, Schuster V, Warnatz K, Grimbacher B, Meinhardt A, Holzinger D, Oommen PT, Hinze T, Hebart H, Seeger K, Lehmberg K, Leahy TR, Claviez A, Vieth S, Schilling FH, Fuchs I, Groß M, Rieux-Laucat F, Magerus A, Speckmann C, Schwarz K, Ehl S; ALPS Study Group. Rensing-Ehl A, et al. Among authors: willenbacher e. J Allergy Clin Immunol. 2024 Jan;153(1):297-308.e12. doi: 10.1016/j.jaci.2023.11.006. Epub 2023 Nov 17. J Allergy Clin Immunol. 2024. PMID: 37979702
Obinutuzumab in multidrug-resistant hairy cell leukemia.
Bohn JP, Willenbacher E, Steurer M. Bohn JP, et al. Among authors: willenbacher e. Ann Hematol. 2016 Jan;95(2):351-2. doi: 10.1007/s00277-015-2520-y. Epub 2015 Oct 7. Ann Hematol. 2016. PMID: 26446506 No abstract available.
Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies.
Petzer V, Steiner N, Angelova-Unterberger O, Hetzenauer G, Philipp-Abbrederis K, Willenbacher E, Feistritzer C, Willenbacher W, Rudzki J, Stauder R, Kocher F, Seeber A, Pircher A, Tymoszuk P, Isara C, Egger A, Fux V, Anliker M, Gunsilius E, Nachbaur D, Schmidt S, Wolf D. Petzer V, et al. Among authors: willenbacher e. Hemasphere. 2022 Feb 15;6(3):e686. doi: 10.1097/HS9.0000000000000686. eCollection 2022 Mar. Hemasphere. 2022. PMID: 35187405 Free PMC article. No abstract available.
29 results